Another study focused one IL-6 inhibitor, ziltivekimab, which has been demonstrated to be effective in reducing inflammatory and thrombotic biomarkers in patients over 18 years of age with chronic stage 3-5 kidney disease or high-sensitivity C-reactive protein (CRP) levels greater than 2 mg/L, without significant adverse effects (15). The gene discussed is CRP; the disease is kidney disorder.